Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 9/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7980918 | 1.00 | ITGB3 (0.52) | ITGB3ITGA2BMEN1KMT2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL8488362 | 0.85 | ITGB3 (0.56) | ITGB3ITGA2BMEN1KMT2ACYP3A4 | |
| SCHEMBL7981888 | 0.85 | ITGB3 (0.50) | ITGB3ITGA2BMEN1KMT2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL8489120 | 0.85 | ITGB3 (0.56) | ITGB3ITGA2BMEN1KMT2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL7969557 | 0.85 | ITGB3 (0.56) | ITGB3ITGA2BMEN1KMT2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL7986512 | 0.85 | ITGB3 (0.56) | ITGB3ITGA2BMEN1KMT2ACYP3A4 | |
| SCHEMBL7969640 | 0.85 | ITGB3 (0.46) | ITGB3ITGA2B | |
| SCHEMBL7985139 | 0.85 | ITGB3 (0.49) | ITGB3ITGA2BMEN1KMT2ACYP3A4 | |
| SCHEMBL8489046 | 0.83 | ITGB3 (0.52) | ITGB3ITGA2BMEN1KMT2ACYP3A4 | |
| SCHEMBL7986646 | 0.82 | ITGB3 (0.51) | ITGB3ITGA2BMEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6191282-B1 | DERIVATIVES OF 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC RING IS USED AS ANTICARCINOGENIC AGENT AND ANTICOAGULANT | HOECHST MARION ROUSSEL (DE) | 2001-02-20 | — | — | US | disclosed |
| US-5981492-A | ADMINISTERED TO THE PATIENT TO INHIBIT THROMBOCYTE AGGREGATION, THE METASTASIZATION OF CARCINOMA CELLS, THE BINDING OF OSTEOCLASTS TO THE BONE SURFACE, OR FOR THE TREATMENT OF THROMBOSES | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-11-09 | — | — | US | disclosed |